Study S000382

A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06174779
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 448
Start: 2024-01-03
Primary completion: 2025-08-14
Lead sponsor: Hanmi Pharmaceutical Company Limited
Conditions: Obesity
Interventions: DRUG:HM11260C; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

The percent change of body weight from baseline [baseline, 40 weeks]
The proportion of subjects achieving body weight loss ≥ 5% from baseline [baseline, 40 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.